MEI Pharma reports plans to price public offering of its common shares

Bookrunners Stifel and Cowen help fund clinical development programs

By Devika Patel

Knoxville, Tenn., Oct. 24 - MEI Pharma, Inc. will price a public offering of common stock with a 30-day greenshoe option, according to a preliminary prospectus supplement filed Thursday with the Securities and Exchange Commission.

Stifel and Cowen and Co. are the joint bookrunning managers.

Proceeds will be used for the clinical development programs for Pracinostat, ME-344 and PWT143 and other general corporate purposes.

The oncology company develops therapies for cancer and is based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.